Patients with chronic lymphocytic leukemia with the 17p deletion have a poor prognosis and treatment options are limited. Venetoclax, a novel B-cell lymphoma-2 inhibitor, has been approved for treatment-experienced chronic lymphocytic leukemia patients with the 17p deletion. A phase 1 dose-escalation study to 400 mg daily showed overall response rates across all doses of 79% with a complete response achieved in 20%. A phase 2 multicenter open-label study demonstrated overall response rate of 79.4% of patients (95% confidence interval 70.5–86.6) with median duration of follow-up of 12.1 months (IQR 10.1-14.2). Tumor lysis syndrome has been observed during initiation and titration. Assessing risk of tumor lysis syndrome prior to therapy initiation is essential to provide appropriate prophylactic medications. Neutropenia, potentially warranting dose reduction or discontinuation, has been observed. Venetoclax has demonstrated activity in other leukemias, multiple myeloma, and lymphomas. Venetoclax has shown response, and is well tolerated in patients with highly resistant chronic lymphocytic leukemia. It has the potential to be part of the treatment armamentarium for other malignancies.
SiegelRLMillerKDJemalAJ. Cancer statistics 2017. Ca Cancer J Clin2017; 67: 7–30.
2.
CramerPLangerbeinsPEichhorstBet al.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL study group (GCLLSG). Eur J Haematology2016; 96: 9–18.
3.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma v.2.2017, www.nccn.org/professionals/physician_gls/pdf/cll.pdf (2017, accessed 2 June 2017).
4.
DohnerHStilgenbauerSBennerAet al.Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med2000; 343: 1910–1916.
5.
StilgenbauerSZenzTWinklerDet al.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2009; 27: 3994–4001.
6.
ByrdJCFurmanRRCoutreSEet al.Three-year follow-up of treatment naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood2015; 125: 2497–2506.
7.
Venclexta (venetoclax tablets, for oral use) prescribing information. North Chicago, IL. AbbVie Inc. April 2016, www.rxabbvie.com/pdf/venclexta.pdf (2016, accessed 2 June 2017).
8.
Shamas-DinABrahmbhattHLeberBet al.BH-3 only proteins: orchestrators of apoptosis. Biochimica et Biophysica Acta2011; 1813(4): 508–520.
9.
StrasserACorySAdamsJM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J2011; 30: 3667–3683.
10.
RobertsAWSeymourJFBrownJRet al.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol2012; 30: 488–496.
11.
SouersAJLeversonJDBoghaertERet al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med2013; 19: 202–208.
12.
RobertsAWDavidsMSPagelJMet al.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med2016; 374: 311–322.
13.
SalemAHAgarwalSKDumbarMet al.Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor. J Clin Pharmacol2016; 56: 1355–1361.
14.
SalemAHAgarwalSKDumbarMet al.Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin’s lymphoma. J Clin Pharmacol2017; 57: 484–492.
15.
JonesAKFreiseKGAgarwalSKet al.Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J2016, pp. 1192–1202.
16.
StilgenbauerSEichhorstBScheteligJet al.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol2016; 17: 768–778.
17.
DavidsMSRobertsAWSeymourJFet al.Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol2016; 34(suppl): abstract 7527–7527.
18.
JonesJAWierdaWGChoiMYet al.Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. J Clin Oncol2016; 34(suppl): abstract 7519–7519.
19.
JonesJChoiMYMatoARet al.Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood2016; 128: 637–637.
20.
MatoARHillBTLamannaNet al.Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients. Ann Oncol2017; 28: 1050–1056.
21.
SeymoreJFMaSBranderDMet al.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol2017; 18: 230–240.
22.
JonesJAWoyachJAwanFTet al.Phase 1b results of a phase 1b/2 study of obinutuzumab, lbrutinib, and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL). Blood2016; 128: 639–639.
23.
FischerKAl-SawafOFinkAMet al.Safety and efficacy of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions: Final results of the run-in phase of the randomized CLL14 trial (BO25323). Blood2016; 128: 2054–2054.
24.
CramerPVon TresckowJBahloJet al.Low incidence of tumor lysis syndromes (TLS) and infusion related reactions (IRR) in the CLL2-Bag trial evaluating a sequential treatment of bendamustine (B), obinutuzumab (GA101, G) and venetoclax (ABT-199, A) in patients with chronic lymphocytic leukemia (CLL): interim safety results of a phase-II-trial of the German CLL study group (GCLLSG). Blood2016; 128: 2044–2044.
25.
StilgenbauerSMorschhauserFWendtherCMet al.Phase 1b study (GO28440) of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood2016; 128: 4393–4393.
26.
AgarwalSKHuBChienDet al.Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a blc-2 inhibitor: Results of a single- and multiple-dose study. J Clin Pharmacol2016; 56: 1335–1343.
27.
AgarwalSKDiNardoCDPotluriJet al.Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther2017; 39: 359–367.
28.
SalemAHHuBFreiseKJet al.Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig2017; 37: 303–309.
29.
FreiseKJDunbarMJonesAKet al.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol2016; 78: 847–853.
PanRHogdalLJBenitoJMet al.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov2014; 4: 362–375.
32.
LeversonJDPhillipsDCMittenMJet al.Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med2015; 7: 279ra40–279ra40.
33.
LagadinouEDSachACallahanKet al.BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell2013; 12: 329–341.
34.
ChanSMThomasDCorces-ZimmermanMRet al.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med2015; 21: 178–184.
35.
KonoplevaMPollyeaDAPotluriJet al.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov2016; 6: 1–12.
36.
BogenbergerJMDelmanDHansenNet al.Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma2015; 56: 226–229.
37.
TsaoTShiYKornblauSet al.Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol2012; 91: 1861–1870.
38.
DiNardoCPollyeaDPratzKet al.A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood2015; 126: 327–327.
39.
LinTLStricklandSAFiedlerWet al.Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. J Clin Oncol2016; 34(suppl): abstract 7007–7007.
40.
KumarSVijRKaufmanJLet al.Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Blood2016; 128: 488–488.
41.
MatulisSMGuptaVANookaAKet al.Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia2015; 30: 1086–1093.
42.
BajpaiRMatulisSMWeiCet al.Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. Epub ahead of print 7 December 2015. DOI: 10.1038/onc.2015.464.
43.
MoreauPChanan-KhanARobertsAWet al.Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood2015; 126: 3038–3038.
44.
AlfordSEKothariALoeffFCet al.BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res2015; 75: 1366–1375.
45.
PeirsSMatthijssensFGoossensSet al.ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood2014; 124: 3738–3747.
46.
LeonardJTRowleyJSJEideCA. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia. Sci Transl Med2016; 8: 354ra114–354ra114.
47.
GerecitanoJFRobertsAWSeymourJFet al.A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood2015; 126: 254–254.
48.
DavidsMSet al.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol2017; 35: 826–833.
49.
de VosSSwinnenLKozloffMet al.A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin’s lymphoma. Blood2015; 126: 255–255.
50.
TamCSLRobertsAWAndersonMAet al.Combination ibrutinib (Ibr) and venetoclax (ven) for the treatment of MCL: primary endpoint assessment of the phase 2 AIM study. J Clin Oncol2017; 35(suppl): abstract 7520–7520.
